The global tumor ablation market size is calculated at USD 2.18 billion in 2025 and is forecasted to reach around USD 6.74 billion by 2034, accelerating at a CAGR of 13.38% from 2025 to 2034. The North America tumor ablation market size surpassed USD 690 million in 2024 and is expanding at a CAGR of 13.42% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Tumor Ablation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Tumor Ablation Market, by Technology
8.1.1 Radiofrequency Ablation
8.1.1.1. Market Revenue and Forecast
8.1.2. Microwave Ablation
8.1.2.1. Market Revenue and Forecast
8.1.3. Cryoablation
8.1.3.1. Market Revenue and Forecast
8.1.4. Irreversible Electroporation Ablation
8.1.4.1. Market Revenue and Forecast
8.1.5. HIFU
8.1.5.1. Market Revenue and Forecast
8.1.6. Other ablation technologies
8.1.6.1. Market Revenue and Forecast
9.1. Tumor Ablation Market, by Treatment
9.1.1. Surgical Ablation
9.1.1.1. Market Revenue and Forecast
9.1.2. Laparoscopic Ablation
9.1.2.1. Market Revenue and Forecast
9.1.3. Percutaneous Ablation
9.1.3.1. Market Revenue and Forecast
10.1. Tumor Ablation Market, by Application
10.1.1. Kidney Cancer
10.1.1.1. Market Revenue and Forecast
10.1.2. Liver cancer
10.1.2.1. Market Revenue and Forecast
10.1.3. Breast cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Lung cancer
10.1.4.1. Market Revenue and Forecast
10.1.5. Prostate cancer
10.1.5.1. Market Revenue and Forecast
10.1.6. Other cancer
10.1.6.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology
11.1.2. Market Revenue and Forecast, by Treatment
11.1.3. Market Revenue and Forecast, by Application
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology
11.1.4.2. Market Revenue and Forecast, by Treatment
11.1.4.3. Market Revenue and Forecast, by Application
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology
11.1.5.2. Market Revenue and Forecast, by Treatment
11.1.5.3. Market Revenue and Forecast, by Application
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology
11.2.2. Market Revenue and Forecast, by Treatment
11.2.3. Market Revenue and Forecast, by Application
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology
11.2.4.2. Market Revenue and Forecast, by Treatment
11.2.4.3. Market Revenue and Forecast, by Application
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology
11.2.5.2. Market Revenue and Forecast, by Treatment
11.2.5.3. Market Revenue and Forecast, by Application
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology
11.2.6.2. Market Revenue and Forecast, by Treatment
11.2.6.3. Market Revenue and Forecast, by Application
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology
11.2.7.2. Market Revenue and Forecast, by Treatment
11.2.7.3. Market Revenue and Forecast, by Application
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology
11.3.2. Market Revenue and Forecast, by Treatment
11.3.3. Market Revenue and Forecast, by Application
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology
11.3.4.2. Market Revenue and Forecast, by Treatment
11.3.4.3. Market Revenue and Forecast, by Application
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology
11.3.5.2. Market Revenue and Forecast, by Treatment
11.3.5.3. Market Revenue and Forecast, by Application
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology
11.3.6.2. Market Revenue and Forecast, by Treatment
11.3.6.3. Market Revenue and Forecast, by Application
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology
11.3.7.2. Market Revenue and Forecast, by Treatment
11.3.7.3. Market Revenue and Forecast, by Application
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology
11.4.2. Market Revenue and Forecast, by Treatment
11.4.3. Market Revenue and Forecast, by Application
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology
11.4.4.2. Market Revenue and Forecast, by Treatment
11.4.4.3. Market Revenue and Forecast, by Application
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology
11.4.5.2. Market Revenue and Forecast, by Treatment
11.4.5.3. Market Revenue and Forecast, by Application
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology
11.4.6.2. Market Revenue and Forecast, by Treatment
11.4.6.3. Market Revenue and Forecast, by Application
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology
11.4.7.2. Market Revenue and Forecast, by Treatment
11.4.7.3. Market Revenue and Forecast, by Application
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology
11.5.2. Market Revenue and Forecast, by Treatment
11.5.3. Market Revenue and Forecast, by Application
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology
11.5.4.2. Market Revenue and Forecast, by Treatment
11.5.4.3. Market Revenue and Forecast, by Application
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology
11.5.5.2. Market Revenue and Forecast, by Treatment
11.5.5.3. Market Revenue and Forecast, by Application
12.1. Boston Scientific Corporation (U.S.)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Medtronic (U.S.)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Olympus (Germany)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Stryker (U.S.)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Biotronik (Germany)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merit Medical Systems. (Utah)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. HealthTronics, Inc. (U.S.)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Insightec. (Israel)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AngioDynamics. (New York)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Integra LifeSciences (U.S.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample